What Gaviscon Extra Strength 500 Treats: Main Uses and Benefits

The Gaviscon Extra Strength formulation is considered relevant for the management of acid-related symptoms of gastroesophageal reflux. This medicine is commonly used to help with symptomatic relief from symptoms related to inflammatory or irritative states of the esophagus. It is relevant for managing symptoms that interfere with daily comfort, such as the painful retrosternal burning sensation (heartburn) and the sour taste of acid regurgitation.

It is relevant for managing symptoms that interfere with daily comfort, and may assist with easing the overall symptom load.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as those triggered by specific dietary choices or positional changes. It is used to help manage symptoms linked to acid-related dyspepsia and is highly relevant for conditions involving episodic or fluctuating manifestations, including pregnancy-related heartburn. This supportive relief assists with maintaining functional stability and may help patients cope more steadily with symptom fluctuations, particularly by managing post-meal discomfort and nocturnal reflux symptoms that interfere with routine activities and rest.

Regulatory References

1. FDA Verification Portal Summary of Product Characteristics

Regulatory documents define specific populations who are eligible to use Gaviscon Extra Strength 500 and those for whom use is contraindicated or requires medical consultation.

Eligibility Scope

Condition-Specific Restrictions

Official labeling requires caution or medical consultation for certain existing conditions due to the product’s composition:

• Kidney Function: Patients with severe renal impairment or renal failure should consult a doctor before use, as components like aluminum and magnesium may accumulate.
• Electrolyte/Metabolic Status: Consultation is necessary for individuals with conditions like hypercalcaemia, nephrocalcinosis, or recurrent calcium-containing renal calculi due to the calcium content. Furthermore, formulations containing aspartame are not suitable for patients with phenylketonuria (PKU).

The overall eligibility structure is based on age and the absence of high-risk medical conditions or hypersensitivities, ensuring the medicine is limited to an appropriate consumer population.

Interactions with Other Medicines and Products: Official Regulatory Information

The official interaction profile for Gaviscon extra strength 500 (containing Calcium Carbonate, Sodium Alginate, and Sodium Bicarbonate) is defined by its capacity to interfere with the absorption and clearance of co-administered medicines. The active components can reduce the bioavailability of other drugs through binding (chelation) and altering gastric pH.

Officially Documented Interactions and Restrictions

• Absorption Interference: Co-administration may result in decreased plasma concentration (reduced exposure) of Quinolone and Tetracycline antibiotics, as well as drugs requiring an acidic environment for dissolution, such as Itraconazole and Atazanavir.
• Systemic Clearance: The Sodium Bicarbonate component may systemically alter urinary pH. This can affect the renal clearance of other drugs, potentially increasing the exposure of basic drugs (e.g., Quinidine) or decreasing the exposure of acidic drugs (e.g., Salicylates).
• Contraindicated Combination: The combination with Eltrombopag is explicitly classified as contraindicated in regulatory documentation, requiring strict time separation.
• Administration Timing Rules: Regulatory documents mandate that all other oral medicines must be administered with a separation of at least two hours from this product. A mandatory separation of at least four hours is required for co-administration with Eltrombopag.
• Substance Cautions: The product's calcium component may inhibit the absorption of Iron Supplements, requiring spaced dosing. Interaction risks are also heightened in patients with renal impairment due to decreased clearance of the Sodium Bicarbonate component.

Gaviscon extra strength 500 contains alginic acid, sodium bicarbonate, and calcium carbonate. The components initiate chemical reactions upon contact with gastric acid, the primary biological target. Alginic acid reacts to form a viscous, low-density gel, known as the 'raft,' which floats on the gastric contents. The sodium bicarbonate facilitates this process by releasing carbon dioxide, which causes the raft to lift and solidify, contributing to its positional maintenance at the gastroesophageal junction. Concurrently, the calcium carbonate component is a neutralizer that mediates the chemical buffering of excess hydrogen ions within the gastric environment. The dual mechanism of action involves the formation of this floating physical barrier, which mechanically impedes the retrograde movement of gastric contents, acid, and pepsin into the esophagus, alongside the chemical neutralization of gastric acid.

How Gaviscon Extra Strength 500 is Used

This medicine is defined by official usage patterns that dictate the required route, dosing schedule, and specific administration conditions. The product is approved for oral administration and is typically available as a chewable tablet or an oral suspension.

Official Dosing and Frequency

Administration and Procedural Rules

The usage protocol is based on intermittent administration, meaning it is taken as needed when symptoms occur. Continuous use at the maximum dose is restricted to a 2-week period unless a regimen modification is advised by a healthcare professional.

For proper administration, chewable tablets must be chewed thoroughly before swallowing, while the oral suspension must be shaken well prior to dispensing.

Usage guidelines limit administration to adults and children 12 years of age and over. Administration to children under 12 years is only permitted following specific medical advice. A procedural constraint involves maintaining a 2-hour interval between the intake of this product and certain other oral medications.

Research Evidence / Overview of Studies for Gaviscon Extra Strength 500

Evidence for Symptomatic Heartburn and Acid Regurgitation

Research exploring this combination of ingredients (sodium alginate, calcium carbonate, and sodium bicarbonate) has primarily focusing on research exploring acid reflux symptoms in adults. Studies conducted have included Randomized Controlled Trials (RCTs), which are an established research design, along with systematic reviews that bring together findings from multiple trials. These studies were applied in research exploring how symptoms change over time, assessing outcomes related to physical discomfort and patterns of episodic or acute changes.

Studies were applied to examine short-term symptom patterns, typically involving observation periods of 7 days to 4 weeks. Findings describe patterns observed in the studies over defined short-term periods, and research highlights changes measured during the study period when compared to a placebo or simple antacids. The available data show patterns related to temporary changes in symptoms.

Research in Specific Patient Groups

Specific research has been dedicated to studying this combination for pregnancy-related heartburn, which is a condition associated with acute or disruptive episodes. Studies conducted during periods of increased symptom activity in pregnant women, primarily in the second and third trimesters, were used in research contexts involving fluctuating or unstable symptoms.

Studies monitored these populations over short-term treatment periods, typically up to two weeks, and sometimes compared the results to other non-prescription antacid products. Research focusing on episodes where symptoms become more noticeable in this specific group contributes to the broader evidence landscape related to short-term changes. Evidence is limited for other specific populations, such as children, and subgroup findings are uncertain for certain groups.

Overview of Research Limitations and Uncertainty

Follow-up durations were limited in many of the primary studies. There is limited information for long-term outcomes, meaning the effects of continuous or repeated use over many months are not fully established. Certainty remains low regarding the full scope of use, as the evidence quality varies across studies. Key research limitation frames include the fact that the results apply only to the populations studied and research does not determine whether an individual will respond similarly.

Key Studies & References

1. The Clinical Efficacy of a Pure Alginate Formulation (Lamina G) for Controlling Symptoms in Individuals with Reflux Symptoms: A Randomized Clinical Study
2. GAVISCON EXTRA STRENGTH peppermint flavour chewable tablet bottle (456108)

Common questions about Gaviscon extra strength 500 (FAQ)

Q: What's the difference between Gaviscon Extra Strength 500 and the liquid Gaviscon?

Some liquid suspensions may contain different active ingredients, such as aluminum hydroxide or magnesium carbonate, instead of the sodium alginate, sodium bicarbonate, and calcium carbonate found in the chewable tablets. The differences between the tablet and liquid forms of Gaviscon Extra Strength can vary significantly depending on the region. Information regarding the active ingredients and formulation can be found on the product label.

Q: Is Gaviscon Extra Strength 500 safe to use every day?

Official labeling advises against taking the maximum daily dose for more than two weeks continuously unless a healthcare professional has provided a different regimen. Continuous daily use at the maximum dose is restricted by labeling, and prolonged exposure can be associated with certain risks, such as hypercalcaemia.

Q: Does Gaviscon Extra Strength 500 contain aluminum?

The active ingredients in many formulations of Gaviscon Extra Strength 500 are sodium alginate, sodium bicarbonate, and calcium carbonate, which do not contain aluminum. However, certain versions of 'Gaviscon Extra Strength' sold in regions like North America may contain aluminum hydroxide and magnesium carbonate. The specific active ingredients are listed on the product’s packaging.

Q: Is it normal to feel a chalky taste after taking Gaviscon Extra Strength 500?

A chalky taste is an adverse effect occasionally reported with antacid-containing products, including those that use mineral components like calcium carbonate. This is often due to the physical nature of the ingredients. If the taste is disruptive or concerning, contact a healthcare provider for guidance.

Q: Does Gaviscon Extra Strength 500 contain sodium and should people with high blood pressure be concerned?

Yes, this medicine contains sodium, derived from the sodium bicarbonate and sodium alginate components. Official labeling includes a warning for patients on a strictly controlled low-sodium diet. Consultation with a healthcare professional is necessary to determine if the product’s sodium content is appropriate for individuals managing high blood pressure or restricted sodium intake.

Q: What happens if I take Gaviscon Extra Strength 500 close to other medications?

Regulatory warnings state that taking the product too closely to other oral medicines may result in decreased absorption and reduced effectiveness of the other drug. This is because the calcium and alginate components can bind to the other medication or alter stomach acidity, inhibiting its absorption.

Q: Why do people say Gaviscon Extra Strength 500 has a 'rafting' action?

The term 'rafting' refers to the unique physical mechanism of action described in official documents. When the product mixes with stomach acid, it rapidly forms a viscous, low-density gel, referred to as a 'raft' or 'floating layer.' This barrier floats atop the stomach contents, physically impeding the flow of acid into the esophagus.

Q: Is it possible to be allergic to an ingredient in Gaviscon Extra Strength 500?

Use of the product is contraindicated for individuals with a known or suspected hypersensitivity to any of the active substances or inactive ingredients (excipients). Allergic reactions, such as hives or rash, are listed in regulatory documents as rare adverse effects.

Q: What is the shelf life of Gaviscon Extra Strength 500 once the bottle is opened?

For the liquid oral suspension, regulatory instructions state that the medicine must be used within six months after the bottle has been opened. For chewable tablets, storage is governed by the printed expiration date on the package. All forms should be stored out of the sight and reach of children and kept at room temperature.

Q: Is Gaviscon Extra Strength 500 lactose-free or gluten-free?

Excipient lists show that some formulations of the chewable tablets may contain 'gluten from wheat' (though typically in low amounts). This indicates the product is not guaranteed to be 100% gluten-free. The inactive ingredients list on the packaging should be reviewed for specific allergen warnings.

Q: Can I take Gaviscon Extra Strength 500 if I have a history of kidney stones?

Official warnings require consultation with a doctor or caution for individuals with recurrent calcium-containing renal calculi (kidney stones) due to the calcium component. Long-term, high-dose use of calcium-containing products may potentially worsen these conditions.

Q: Do Gaviscon Extra Strength 500 tablets contain sugar or artificial sweeteners?

Yes, regulatory listings for the tablets indicate they often contain both artificial sweeteners and, in some cases, sugar (sucrose) or sugar alcohols. Common sweeteners include saccharin sodium and aspartame, the latter of which is a source of phenylalanine, relevant for patients with phenylketonuria (PKU).

Q: Can Gaviscon Extra Strength 500 cause dizziness or lightheadedness?

Dizziness or lightheadedness is not listed among the common side effects of the product. However, regulatory documents state that dizziness has been reported very rarely as a possible symptom associated with a hypersensitivity (allergic) reaction.

Q: Is Gaviscon Extra Strength 500 suitable for someone with a low-sodium diet?

Because the product contains sodium from sodium alginate and sodium bicarbonate, official labeling mandates caution for individuals on a strictly controlled low-sodium diet. Consultation with a healthcare professional is necessary to determine suitability for individuals on a strictly controlled low-sodium diet.

Q: Does Gaviscon Extra Strength 500 cause gas or bloating?

The official documentation on side effects lists 'Gastrointestinal Disorders' such as flatulence (gas) and constipation. Bloating is a common symptom associated with increased gas in the digestive system, which may occur due to these effects.

Q: What is the active strength of the sodium alginate component in Gaviscon Extra Strength 500?

The active strength of the sodium alginate component is typically 500 mg per chewable tablet or per 10 mL of the liquid suspension. The full strength of all active ingredients is listed on the product’s packaging under the 'Active Ingredients' section.

Q: Does Gaviscon Extra Strength 500 help with nighttime heartburn?

The official dosing instructions specify that the product can be taken at bedtime, in addition to being taken after meals. This indicates that the medicine is used for the treatment of symptoms, such as heartburn and acid regurgitation, that may occur during the night.

Q: Why do people recommend taking Gaviscon Extra Strength 500 after meals?

The official dosing schedules advise taking the product after meals. The mechanism of action requires the product to form a physical 'raft' on top of the stomach contents. Taking the medicine after a meal ensures there are sufficient contents in the stomach for the raft to form effectively and float in the correct position to protect the esophagus.

Q: Does Gaviscon Extra Strength 500 have any impact on blood calcium levels?

Because the product contains calcium carbonate, there is a potential for impact on blood calcium levels. Official warnings state that hypercalcaemia (abnormally high blood calcium) is a risk, particularly when the medicine is used at high doses for prolonged periods or in individuals with impaired kidney function.

How to Store and Dispose of Gaviscon Extra Strength

Official regulatory guidelines mandate specific conditions for storing this medicine to maintain its stability and effectiveness, with requirements differing by formulation.

Storage and Stability

Both the chewable tablets and the liquid oral suspension must be stored at a controlled room temperature, typically up to 25°C (77°F). The tablets must be kept in a dry place. The liquid suspension is explicitly mandated to avoid freezing and not be refrigerated, and once opened, it must be used within 6 months.

Protection and Disposal

All forms of the medicine must be stored out of the sight and reach of children. The liquid container must be kept tightly closed.

For disposal, official instructions prohibit discarding unused or expired Gaviscon Extra Strength via wastewater or household waste. Instead, the user is required to consult a pharmacist for guidance on proper pharmaceutical waste disposal.